The Oncology Institute (TOI) Q1 2026 earnings review
Pharmacy Boom Drives Revenue, Free Cash Flow Outlook Surges
The Oncology Institute (TOI) delivered a robust 41% YoY revenue increase to $147.4M, handily proving the scalability of its integrated care model. The top-line growth was overwhelmingly driven by a 78% explosion in Specialty Pharmacy revenue. Earnings quality improved dramatically as well, with the net loss shrinking from $19.6M a year ago to just $2.5M. While Q1 saw a seasonal reversion to an Adjusted EBITDA loss of $2.4M (due to deductible resets), management successfully pushed its Florida operations into profitability. The biggest news for investors: a massive upward revision to FY26 Free Cash Flow guidance, moving from a previous midpoint of negative $5M to a positive $10M, signaling the company's cash-burn phase is effectively ending.
🐂 Bull Case
The $20M positive swing in FY26 Free Cash Flow guidance (at the midpoint) indicates dramatic working capital improvements and diminishing capital needs. TOI is no longer a cash-burning story.
Achieving profitability in Florida proves that the company's delegated capitation model can scale and mature into a highly profitable engine outside of its legacy California base.
🐻 Bear Case
While total revenue jumped 41%, core Patient Services grew only 11% YoY. The company is becoming heavily reliant on drug dispensing rather than its core care delivery services.
Management explicitly warned that tariff rate increases could impact world trade, which introduces supply chain and drug pricing risks for a business increasingly dependent on pharmacy margins.
⚖️ Verdict: 🟢
Bullish. The 78% growth in the high-margin Specialty Pharmacy segment is more than compensating for any sluggishness in patient services. A structural shift to positive Free Cash Flow fundamentally changes the investment profile for the better.
Key Themes
Specialty Pharmacy is the Growth Engine
Specialty Pharmacy revenue accelerated to $87.5M, a massive 78% YoY increase. This segment now accounts for 59% of total revenue, up from 47% a year ago. The growth is fueled by record Part D fills and systemic improvements in prescription attachment rates across TOI's growing capitated member base. This mix shift is structurally improving gross profit dollars.
Florida Market Achieves Profitability
A pivotal milestone: TOI's Florida operations reached profitability in Q1. This proves that their delegated capitation model works. Furthermore, the company announced contract expansions that will bring total Medicare Advantage lives to 200,000 across 25 Florida counties effective July 1, 2026, ensuring a massive revenue runway in H2 2026.
Proprietary Provider Portal Launch
TOI is preparing to launch a proprietary provider portal this summer. This tool acts as an internal SaaS product to strengthen provider engagement and enforce adherence to clinical pathways. Better pathway adherence directly translates to lower Medical Loss Ratios (MLR) and higher profitability on capitated contracts.
CMS Enhancing Oncology Model Success
The company saved approximately $2M in Medicare spending under the CMS Enhancing Oncology Model in period 3. This is a critical proof point for payers, demonstrating TOI's ability to maintain high-quality care while successfully bending the cost curve in oncology.
Q1 Seasonality Breaks Profitability Streak
Despite narrative momentum around reaching profitability in late 2025, Q1 2026 Adjusted EBITDA reversed back to a loss of $2.4M (compared to a $0.15M profit in 25Q4). While management blames normal seasonality and deductible resets, this highlights the fragility of TOI's current margin profile during the early months of the year.
Clinical Trials Collapse
Revenue from the 'Clinical trials & other' segment plummeted 60% YoY to just $0.8M from $2.0M in Q1 25. This reflects the fallout from last year's decision to outsource and write off the clinical trials business. While small, this eliminates a high-margin, adjacent revenue stream.
Tariff and Macro Supply Chain Risks
Management explicitly flagged that recent tariff rate increases and exchange rate changes could negatively affect world trade and, consequently, their business. Given TOI's increasing reliance on drug dispensing for growth, any disruption or cost inflation in the pharmaceutical supply chain due to tariffs could severely compress margins.
Other KPIs
Accelerating in absolute dollars, growing 35.2% YoY. However, gross margin actually compressed slightly to 15.8% (down from 16.5% in 25Q1). This is a result of the revenue mix shifting heavily toward the Specialty Pharmacy, which carries strong absolute dollar contribution but a lower percentage margin than fee-for-service patient care.
Selling, general and administrative expenses grew 11.2% YoY (from $25.4M in Q1 25). However, as a percentage of revenue, SG&A improved drastically to 19.1% from 24.3% a year ago. This demonstrates significant operating leverage and cost discipline as the top line scales.
Guidance
Reversing. Management drastically updated this metric from a prior guide of $(15)M to $5M. At the $10M midpoint, this implies a massive swing from the $(23.9)M burn in FY25. This suggests working capital optimization and reduced capital expenditures are taking hold faster than anticipated.
Stable. Management left this guidance unchanged. The $640M midpoint implies a 27% YoY growth rate over FY25's $502.7M. Given Q1 delivered 41% YoY growth, this guidance looks conservative and implies a deceleration in the back half of the year, likely due to base effects.
Accelerating. Unchanged from prior guidance, the $4.5M midpoint implies a complete turnaround from the $(12.4)M loss in FY25. Achievability depends heavily on Florida MA lives ramping seamlessly in H2 2026.
Accelerating sequentially. This reflects expected seasonal improvement as patient deductibles are satisfied and the delegated Florida lives continue to ramp. The midpoint ($0) implies a breakeven quarter following the $(2.4)M loss in Q1.
Key Questions
Free Cash Flow Revision Driver
You revised FY26 Free Cash Flow guidance upward by $20 million at the midpoint, yet left Adjusted EBITDA unchanged. What specific working capital dynamics or capex reductions drove this massive improvement?
Margin Ceilings in Pharmacy
Specialty Pharmacy grew 78% YoY and is clearly driving top-line outperformance. As this becomes a larger part of the mix, what is the steady-state gross margin expectation for this segment, especially considering tariff or supply chain risks you flagged?
Florida Expansion Economics
With the Florida market reaching profitability in Q1, how should we model the margin drag from the 200,000 Medicare Advantage lives coming online in July? Will there be an initial 'continuity of care' pressure before MLRs normalize?